Markets

Valion Bio's Velocity Biowork Subsidiary Completes Initial Feasibility Evaluation Of LarmorBio's BioScan-NMR Platform

Oct 15, 2026 · 08:01 AM ET· updated 1h ago

Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company") and LarmorBio, Inc. ("LarmorBio") today announced that Velocity Bioworks, Valion's wholly owned biologics contract development and

Why It Matters

Valion's lab tested a new scanning technology to see if it could work. When companies explore new tools, it shows they are trying to grow their business.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

VBIO1.24

-0.21 (-14.48%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.